Effect of blood donor characteristics on transfusion outcomes: A systematic review and meta-analysis

Transfusion Medicine Reviews

Volumn 30, Issue 2, 2016, Pages 69-80

  Chassé, Michaël ^a   McIntyre, Lauralyn ^a   English, Shane W ^a   Tinmouth, Alan ^a   Knoll, Greg ^a   Wolfe, Dianna ^a   Wilson, Kumanan ^a   Shehata, Nadine ^b   Forster, Alan ^c   van Walraven, Carl ^a   Fergusson, Dean A ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Blood donors; Outcomes; Red blood cells; Systematic review; Transfusion

Indexed keywords

HLA DR ANTIGEN; ALLOANTIBODY; HLA ANTIGEN;

ACUTE LUNG INJURY; ALLOIMMUNIZATION; BLOOD DONOR; BLOOD TRANSFUSION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; HUMAN; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; META ANALYSIS; PROSPECTIVE STUDY; QUALITY CONTROL; RECIPIENT; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; AGE; DONOR SELECTION; EVIDENCE BASED MEDICINE; FEMALE; HOSPITAL MORTALITY; IMMUNOLOGY; MALE; METHODOLOGY; OBSERVATIONAL STUDY; SEX FACTOR; STATISTICAL BIAS; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TRANSMISSION; TREATMENT OUTCOME; VIREMIA;

AGE FACTORS; BIAS; BLOOD DONORS; DONOR SELECTION; ERYTHROCYTE TRANSFUSION; EVIDENCE-BASED MEDICINE; FEMALE; HLA ANTIGENS; HOSPITAL MORTALITY; HUMANS; ISOANTIBODIES; MALE; OBSERVATIONAL STUDIES AS TOPIC; RESEARCH DESIGN; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIREMIA;

EID: 84962519478     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2016.01.002     Document Type: Review

References (73)

1. WHO Blood safety and availability. WHO Glob Database Blood Saf 2014, http://www.who.int/mediacentre/factsheets/fs279/en.
2. Gilliss B.M., Looney M.R., Gropper M.A. Reducing noninfectious risks of blood transfusion. Anesthesiology 2011, 115:635-649. 10.1097/ALN.0b013e31822a22d9.
3. Vamvakas E.C., Blajchman M a, Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009, 113:3406-3417. 10.1182/blood-2008-10-167643.
4. O'Brien S.F., Yi Q.-L., Fan W., Scalia V., Fearon M.A., Allain J.-P. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang 2012, 103:83-86. 10.1111/j.1423-0410.2012.01584.x.
5. Toy P., Gajic O., Bacchetti P., Looney M.R., Gropper M.A., Hubmayr R., et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012, 119:1757-1767. 10.1182/blood-2011-08-370932.
6. Chapman C.E., Williamson L.M. National Blood Service TRALI reduction policies: implementation and effect. Transfus Med Hemother 2008, 35:93-96. 10.1159/000119116.
7. Taylor D.O., Stehlik J., Edwards L.B., Aurora P., Christie J.D., Dobbels F., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 2009, 28:1007-1022. 10.1016/j.healun.2009.08.014.
8. Bonser R.S., Taylor R., Collett D., Thomas H.L., Dark J.H., Neuberger J. Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry. Lancet 2012, 380:747-755. 10.1016/S0140-6736(12)60160-3.
9. Rayhill S.C., Wu Y.M., Katz D.A., Voigt M.D., Labrecque D.R., Kirby P.A., et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007, 84:331-339. 10.1097/01.tp.0000270313.31328.63.
10. Kollman C., Howe C.W., Anasetti C., Antin J.H., Davies S.M., Filipovich A.H., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051. 10.1182/blood.V98.7.2043.
11. Schultz K.R., Green G.J., Wensley D., Sargent M.A., Magee J.F., Spinelli J.J., et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994, 84:3212-3220.
12. Chassé M., English S.W., McIntyre L., Knoll G., Shehata N., Forster A., et al. Effect of blood donor characteristics on transfusion outcomes: a protocol for systematic review and meta-analysis. Syst Rev 2014, 3:28. 10.1186/2046-4053-3-28.
13. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration 2011.
14. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926. 10.1136/bmj.39489.470347.AD.
15. Gajic O., Yilmaz M., Iscimen R., Kor D.J., Winters J.L., Moore S.B., et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med 2007, 35:1645-1648. 10.1097/01.CCM.0000269036.16398.0D.
16. Edgren G., Hjalgrim H., Reilly M., Tran T.N., Rostgaard K., Shanwell A., et al. Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet 2007, 369:1724-1730. 10.1016/S0140-6736(07)60779-X.
17. Lin Y., Saw C.-L., Hannach B., Goldman M. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion 2012, 52:567-574. 10.1111/j.1537-2995.2011.03330.x.
18. Nowlis E., Nathens A.B., Konkle B., Dinwiddie S., Watkins T.R. The effect of red blood cell donor age on lung injury development after hemorrhagic trauma. Transfusion 2012, 52:171A-172A.
19. Porretti L., Cattaneo A., Coluccio E., Mantione E., Colombo F., Mariani M., et al. Implementation and outcomes of a transfusion-related acute lung injury surveillance programme and study of HLA/HNA alloimmunisation in blood donors. Blood Transfus 2012, 10:351-359.
20. Petersen L.R., Satten G.A., Dodd R., Busch M., Kleinman S., Grindon A., et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994, 34:283-289.
21. Manns A., Wilks R.J., Murphy E.L., Haynes G., Figueroa J.P., Barnett M., et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J cancer 1992, 51:886-891.
22. Eder A.F., Herron R.M.J., Strupp A., Dy B., White J., Notari E.P., et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010, 50:1732-1742.
23. Arinsburg S.A., Skerrett D.L., Karp J.K., Ness P.M., Jhang J., Padmanabhan A., et al. Conversion to low transfusion-related acute lung injury (TRALI)-risk plasma significantly reduces TRALI. Transfusion 2012, 52:946-952.
24. Chapman C.E., Stainsby D., Jones H., Love E., Massey E., Win N., et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009, 49:440-452.
25. Eder F., Dy B., Rambaud M., Benjamin R.J. The residual risk of TRALI in a large U.S. blood system reflects the ongoing reliance on AB plasma from female donors to meet demand. Vox Sang 2012, 103:20-21.
26. Poulin C., Tremblay D., Robillard P., Delage G. Comité d'hémovigilance du Québec - Rapport 2010. Quebec City 2011.
27. Insunza A., Romon I., Gonzalez-Ponte M.L., Hoyos A., Pastor J.M., Iriondo A., et al. Implementation of a strategy to prevent TRALI in a regional blood centre. Transfus Med 2004, 14:157-164. 10.1111/j.0958-7578.2004.00492.x.
28. Middelburg R.A., Van S.D., Zupanska B., Uhrynowska M., Gajic O., Muniz-Diaz E., et al. Female donors and transfusion-related acute lung injury. Transfusion 2010, 50:2447-2454.
29. Sanchez R., Bacchetti P., Toy P. Transfusion-related acute lung injury: a case-control pilot study of risk factors. Am J Clin Pathol 2007, 128:128-134.
30. Kulharya A.S., Salbert B.A., Norris K.N., Cook L., Larrison P.J., Flannery D.B. Packed red cell transfusion does not compromise chromosome analysis in newborns. Genet Med 2001, 3:314-317.
31. Middelburg R.A., Briet E., van der Bom J.G. Mortality after sex-mismatched transfusions. Vox Sang 2011, 101:314.
32. Paul D.A., Mackley A., Novitsky A., Zhao Y., Brooks A., Locke R.G. Increased odds of necrotizing enterocolitis after transfusion of red blood cells in premature infants. Pediatrics 2011, 127:635-641.
33. Eder A.F., Herron R., Strupp A., Dy B., Notari E.P., Chambers L.A., et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007, 47:599-607.
34. Middelburg R.A., Briët E., van der Bom J.G. Mortality after transfusions, relation to donor sex. Vox Sang 2011, 101:221-229. 10.1111/j.1423-0410.2011.01487.x.
35. Vlaar A.P.J., Hofstra J.J., Determann R.M., Veelo D.P., Paulus F., Kulik W., et al. The incidence, risk factors, and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case-control study. Blood 2011, 117:4218-4225.
36. Zupanska B., Uhrynowska M., Michur H., Maslanka K., Zajko M. Transfusion-related acute lung injury and leucocyte-reacting antibodies. Vox Sang 2007, 93:70-77.
37. Ambruso D.R., Githens J.H., Alcorn R., Dixon D.J., Brown L.J., Vaughn W.M., et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987, 27:94-98.
38. Heddle N.M., O'Hoski P., Singer J., McBride J.A., Ali M.A., Kelton J.G. A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing. Br J Haematol 1992, 81:579-584.
39. Michail-Merianou V., Pamphili-Panousopoulou L., Piperi-Lowes L., Pelegrinis E., Karaklis A. Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang 1987, 52:95-98.
40. Tahhan H.R., Holbrook C.T., Braddy L.R., Brewer L.D., Christie J.D. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994, 34:562-569.
41. Ameen R., Al Shemmari S., Al-Bashir A. Red blood cell alloimmunization among sickle cell Kuwaiti Arab patients who received red blood cell transfusion. Transfusion 2009, 49:1649-1654. 10.1111/j.1537-2995.2009.02185.x.
42. van der Mast B.J., Balk A.H. Effect of HLA-DR-shared blood transfusion on the clinical outcome of heart transplantation. Transplantation 1997, 63:1514-1519. 10.1097/00007890-199705270-00024.
43. Hiesse C., Busson M., Buisson C., Farahmand H., Bierling P., Benbunan M., et al. Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int 2001, 60:341-349.
44. Albert E.D., Scholz S., Meixner U., Land W. HLA-A, B matching of pretransplant blood transfusion is associated with poor graft survival. Transplant Proc 1981, 13:175-177.
45. Mariat C., Alamartine E., De Filippis J.P., Deprele C., Le Petit J.C., Goure D., et al. Effect of HLA semi-identical pretransplant blood transfusions on renal allograft outcome. Transplant Proc 2000, 32:381-383. 10.1016/S0041-1345(99)00986-0.
46. Christiaans M.H., van Hooff J.P., Nieman F., van den Berg-Loonen E.M. HLA-DR matched transfusions: development of donor-specific T- and B-cell antibodies and renal allograft outcome. Transplantation 1999, 67:1029-1035. 10.1097/00007890-199904150-00016.
47. Vervoordeldonk S.F., Doumaid K., Remmerswaal E.B., ten Berge I.J., Wilmink J.M., de Waal L.P., et al. Long-term detection of microchimaerism in peripheral blood after pretransplantation blood transfusion. Br J Haematol 1998, 102:1004-1009.
48. Middleton D., Martin J., Douglas J., McClelland M. Transfusion of one HLA-DR antigen-matched blood to potential recipients of a renal allograft. vol. 58 1994, 10.1097/00007890-199410150-00017.
49. Baudouin V., de Vitry N., Hiesse C., Lang P., Bloch J., Legouvello S., et al. Cytotoxic T lymphocyte changes after HLA-DR match and HLA-DR mismatch blood transfusions. Transplantation 1997, 63:1155-1160. 10.1097/00007890-199704270-00016.
50. Magee B.A., Martin J., Cole M.P., Morris K.G., Courtney A.E. Effects of HLA-matched blood transfusion for patients awaiting renal transplantation. Transplantation 2012, 94:1111-1116.
51. Scornik J.C., Salomon D.R., Howard R.J., Pfaff W.W. Prevention of transfusion-induced broad sensitization in renal transplant candidates. Transplantation 1989, 47:617-620.
52. van Hooff J.P., Berg-Loonen P.M. The influence of DR match of blood donor and recipient on the formation of T- and B-cell antibodies and on renal allograft outcome. Transpl Int 1992, 5(Suppl. 1):S599-S600.
53. van Twuyver E., Mooijaart R.J., ten Berge I.J., van der Horst A.R., Wilmink J.M., Kast W.M., et al. Pretransplantation blood transfusion revisited. N Engl J Med 1991, 325:1210-1213. 10.1056/NEJM199110243251704.
54. Pass M.A., Johnson J.D., Schulman I.A. Evaluation of a walking donor blood transfusion program in an intensive care nursery. J Pediatr 1976, 89:646-651.
55. Strauss R.G., Burmeister L.F., Johnson K., Cress G., Cordle D.G. Randomized trial assessing the feasibility and safety of biologic parents as RBC donors for their preterm infants. Transfusion 2000, 40:450-456.
56. Middelburg R.A., van Stein D., Atsma F., Wiersum-Osselton J.C., Porcelijn L., Beckers E.A.M., et al. Alloexposed blood donors and transfusion-related acute lung injury: a case-referent study. Transfusion 2011, 51:2111-2117. 10.1111/j.1537-2995.2011.03118.x.
57. Funk M.B., Guenay S., Lohmann A., Henseler O., Heiden M., Hanschmann K.M.O., et al. Benefit of transfusion-related acute lung injury risk-minimization measures-German haemovigilance data (2006-2010). Vox Sang 2012, 102:317-323.
58. Johnson S.T., Cable R.G., Leiby D.A. Lookback investigations of Babesia microti-seropositive blood donors: seven-year experience in a Babesia-endemic area. Transfusion 2012, 52:1509-1516.
59. Young C., Chawla A., Berardi V., Padbury J., Skowron G., Krause P.J. Preventing transfusion-transmitted babesiosis: preliminary experience of the first laboratory-based blood donor screening program. Transfusion 2012, 52:1523-1529.
60. Nichols W.G., Price T.H., Gooley T., Corey L., Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003, 101:4195-4200.
61. Preiksaitis J.K., Desai S., Vaudry W., Roberts S., Akabutu J., Grundy P., et al. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study. Transfusion 1997, 37:941-946.
62. Allain J.P., Mihaljevic I., Gonzalez-Fraile M.I., Gubbe K., Holm-Harritshoj L., Garcia J.M., et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013, 53:1405-1415.
63. Aymard J.P., Janot G., Gayet S., Guillemin C., Canton P., Gaucher P., et al. Post-transfusion non-A, non-B hepatitis after cardiac surgery. Prospective analysis of donor blood anti-HBc antibody as a predictive indicator of the occurrence of non-A, non-B hepatitis in recipients. Vox Sang 1986, 51:236-238.
64. Blajchman M.A., Bull S.B., Feinman S.V. Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study. Group 1995, 345.
65. Beltran M., Navas M.C., De la Hoz F., Mercedes Munoz M., Jaramillo S., Estrada C., et al. Hepatitis C virus seroprevalence in multi-transfused patients in Colombia. J Clin Virol 2005, 34(Suppl. 2):S33-S38.
66. O'Riordan J.M., Conroy A., Nourse C., Yap P.L., McDonald G.S., Kaminski G., et al. Risk of hepatitis C infection in neonates transfused with blood from donors infected with hepatitis C. Transfus Med 1998, 8:303-308.
67. Probability of receiving testing in a national lookback program: the English HCV experience. Transfusion 2002, 42:1140-1145.
68. Vogt M., Muhlbauer F., Braun S.L., Lang T., Busch R., Lange R., et al. Prevalence and risk factors of hepatitis C infection after cardiac surgery in childhood before and after blood donor screening. Infection 2004, 32:134-137.
69. Hladik W., Kataaha P., Mermin J., Purdy M., Otekat G., Lackritz E., et al. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. Trop Med Int Health 2006, 11:951-954.
70. Herr V., Ambruso D., Fairfax M., Neumann A., Swanson P., Lee H. Transfusion-associated transmission of human T-lymphotropic virus types I and II: experience of a regional blood center. Transfusion 1993, 33:208-211.
71. Okochi K., Sato H. Transmission of adult T-cell leukemia virus (HTLV-I) through blood transfusion and its prevention. AIDS Res 1986, 2(Suppl. 1):S157-S161.
72. Sato H., Okochi K. Transfusion transmitted infection of HTLV-I and its prevention. Gann Monogr Cancer Res 1992, 39:151-162.
73. Hourfar M.K., Mayr-Wohlfart U., Themann A., Sireis W., Seifried E., Schrezenmeier H., et al. Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion 2011, 51:129-136.